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approval. RESULTS: PMW who initiated RLX following the IBCRR approval versus 
before approval were less likely to be in the 50–54 age group compared to all other 
age groups (Adjusted Odds Ratio [AOR] = 1.594 [age 55–59], 1.812 [age 60–64], 
1.667 [age 65–69], 1.782 [age 70+]). RLX initiators were more likely to have a lower 
CDS after the IBCRR approval vs. before approval (medium AOR = 0.795 [Conﬁdence 
Interval (CI): 0.711, 0.889], high AOR = 0.71 [CI: 0.626, 0.805]). After the IBCRR 
approval, RLX initiators had a greater likelihood of having a code for family history 
of BC in the claims database (AOR = 1.761 [CI: 1.213, 2.556]) compared to RLX 
initiators before approval. PMW who initiated RLX after IBCRR approval did not 
differ signiﬁcantly from those who initiated before approval with regard to mam-
mograms, fractures, BMD screening, and provider specialty. CONCLUSIONS: PMW 
who initiated RLX after the IBCRR approval were more likely to be older, have a 
lower CDS, and have a family history of BC compared with RLX initiators before 
approval. Factors such as mammograms, fractures, BMD screening, and provider 
specialty did not differ before and after the IBCRR approval.
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OBJECTIVES: The objective of this study was to evaluate the extent to which oncolo-
gist would participate and comply with a P4Q program employing clinical pathways. 
METHODS: A P4Q program was enacted in ﬁve northeastern states, USA, beginning 
August 1, 2008, and consisted of physician generated treatment (i.e. breast, lung, and 
colon-rectal cancer) and supportive care pathways (i.e. colony-stimulating factors, 
erythropoietin stimulating agents, and antiemetics). Practices were informed of the 
program three months in advance and allowed to sign up for the program prior to 
and during the ﬁrst year of the program. Feedback was provided to participants 
regarding compliance, and increased fee schedules in year 1 were adjusted in year 2 
contingent on compliance in year 1. Compliance was measured through the claims 
submitted by participating practices on cancer patients starting a new line of therapy 
after August 1, 2008. Compliance was deﬁned by provision of a drug or regimen not 
according to the deﬁned pathway. RESULTS: A total of 362 physicians were eligible 
for participation (174 community based; 34 hospital based; 154 academic based). 
49% of all physicians, 88% of community based, 44% of hospital based, and 6% of 
academic physicians signed up to participate in the program. 2,119 cancer patients 
were eligible for compliance analysis. Overall 85.9% of patients were judged compli-
ant to treatment pathways (90.5% breast, 90.9% colon, 72.3% lung). Overall 95.4% 
of patients were compliant to supportive care pathways (100% CSF, 98.6% ESAs, 
91.3% antiemetics). CONCLUSIONS: This study suggests high levels of compliance 
with clinical pathways may be achieved. Participation varied greatly by practice type. 
Additional analysis should consider evaluation of alternate deﬁnitions of compliance 
(e.g. errors of omission rather than commission) and reasons for non-participation 
(e.g. overlap of compliance with potential ﬁnancial advantage of participation).
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OBJECTIVES: Quality of care for cancer may improve with information technology 
products such as ELECTRONIC MEDICAL RECORDS (EMR). The objectives of this 
study were 1) to identify aspects of value of EMR use to providers in assessing and 
improving quality cancer care and 2) to identify issues in cost-effectiveness of EMR 
from the provider perspective. METHODS: A systematic literature review regarding 
perceptions of the quality of cancer care in the United States was conducted in 
PubMed, EMBASE, and Cochrane Reviews for the last 10 years, English only articles. 
Oncology medical subject heading (MESH) terms were cross-matched with quality of 
care MESH terms to obtain 875 abstracts. Of these, 140 publications were selected 
for full-article review based on deﬁned inclusion/exclusion criteria. RESULTS: Reports 
of EMR use among hospitals, hospital networks (for example, Veterans Hospital 
Administration), and moderately sized oncology practices indicated that providers 
rapidly obtained information on guideline adherence and determined whether patients 
received follow-up in physician ofﬁces. Cost savings were incurred across multidisci-
plinary teams because fewer tests were duplicated. Business management costs for 
billing were reduced. Other cost savings were lower labor costs due to reduced need 
for medical records staff, and staff to provide information among caregivers and to 
direct patient ﬂow. Cost effectiveness was variable for small physician practices, with 
some providers recovering the cost of the EMR system and others incurring serious 
ﬁnancial problems as a result of implementing EMR use in their practices. CONCLU-
SIONS: EMR may be ﬁnancially challenging for some small physician practices. 
However, it can assist providers in assessing whether their patients are receiving 
guideline-adherent care and aid in more efﬁcient processes of care, thereby improving 
overall quality of cancer care.
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OBJECTIVES: The oncology market has become one of the major focus areas for 
pharmaceutical and biotech ﬁrms. As of March 2009, 15,752 of 39,747 Phase I,II, 
and III trials listed on clinicaltrials.gov, were related to cancer (approximately 40%). 
This large interest in oncology stems from market success of cancer therapies launched 
in the past decade and the existence of high unmet need to treat different types of 
cancers. As the number of FDA approved cancer therapies increases there is a need 
to understand treatment patterns of these cancer drugs. METHODS: To understand 
the trends in usage and sales of cancer therapies we analyzed the US market (sales and 
prescription) 2005–2008 data for all FDA approved cancer drugs. Drugs were catego-
rized as targeted cancer therapies, chemotherapies, monoclonal antibodies, small 
molecules, branded and generics. RESULTS: During the past ﬁve years the usage of 
both targeted cancer therapies and chemotherapy drugs has increased by high double 
digit rates. From 2005–2008, the total prescriptions for targeted cancer therapies and 
chemotherapies increased by 66% and 30%, respectively. While the sales of both types 
of these drugs are expanding, the majority of sales growth is attributed to an increasing 
uptake of targeted cancer drugs. The sales share of targeted cancer therapies in the 
US oncology market increased from 36% in 2004 to 56% in 2008. Among targeted 
cancer therapies, majority (more than 75%) of uptake belongs to monoclonal antibod-
ies. CONCLUSIONS: The usage and sales trends show a signiﬁcant increase in the 
use of cancer drugs. The high usage of targeted cancer therapies versus chemotherapies 
shows the rapidly changing nature of cancer treatment regimen.
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OBJECTIVES: Systemic chemotherapy is a vital component of breast cancer manage-
ment but early-onset toxicities like neutropenia hinder its administration. Primary 
prophylactic (PP) use of granulocyte-colony stimulating factors (G-CSF) helps prevent 
neutropenia and ensures successful chemotherapy completion. Nevertheless, lack of 
speciﬁc guidelines for G-CSF administration in the elderly has lead to unexplained 
geographic and racial, and counter-intuitive clinical variations. For example, older 
individuals with higher co-morbidities (at higher neutropenia risk) have lower prob-
ability of G-CSF receipt. This study examined the reasons for these variations and for 
the ﬁrst time looked at variations in PP administration in breast cancer patients. 
METHODS: A retrospective observational study of newly diagnosed breast cancer 
patients receiving chemotherapy was performed using the 1994–2003 SEER-Medicare 
data. Univariate analyses and multi-variate logistic regressions were used to explore 
the determinants of PPG-CSF administration. Previously unexplored clinical and 
therapeutic characteristics (e.g. chemotherapy characteristics before the administration 
of PPG-CSF) were also included. RESULTS: Univariate analyses demonstrated geo-
graphic, racial and clinical disparities similar to previous studies. However, multi-
variate analyses revealed that controlling for chemotherapy characteristics (type and 
number of drugs and between cycle duration) made the correlation of age and other 
clinical characteristics with PPG-CSF administration insigniﬁcant. Signiﬁcant geo-
graphic and racial disparities existed. Exploration of geographic variations suggested 
that regions with higher rates of PPG-CSF administration have higher proportion of 
physicians administering them; none of the physicians using PPG-CSF administered it 
on a signiﬁcantly higher proportion of their patients. CONCLUSIONS: Physicians’ 
decision to administer PPG-CSF is predominantly driven by neutropenia risk associ-
ated with pre-planned chemotherapy regimen. Older, sicker women at a higher risk 
of neutropenia received less intense/toxic chemotherapy thus did not require PPG-CSF. 
Geographic variations are driven by provider-level variations in PPG-CSF administra-
tion with no evidence for overuse among the providers. Racial and geographic dispari-
ties have no clinical basis and are a matter of concern.
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OBJECTIVES: To examine the prescribing patterns of the recommended pharmaco-
logic treatments for metastatic renal cell carcinoma (mRCC). METHODS: A retrospec-
tive claims-based analysis was conducted that identiﬁed incident mRCC patients 
(18–64 years) in the Thomson Reuters MarketScan Commercial Claims Database 
(January 2005–September 2008). Patients were required to have at least 6 months of 
continuous enrollment before the index date (ﬁrst metastases claim) and at least 30 days 
of continuous enrollment after the index date. Treatment patterns were described as 
proportions of mRCC patients receiving the following guideline-recommended phar-
macologic agents: immunotherapies (interferon-alpha and interleukin-2) and the newer 
targeted agents (sunitinib, sorafenib, bevacizumab, temsirolimus and everolimus), 
either as initial or second-line therapies any time on or after the index date. RESULTS: 
A total of 1390 patients with mRCC were included in the analysis. Mean age was 55.6 
years and 70.5% were male. The mean continuous enrollment after diagnosis of metas-
